{"public_id":"cl_50f79482a0c0ce49639d7297657ba38a","status":"active","superseded_by_public_id":null,"corpus_id":44162853,"text":"Immaturity of survival data and comparator issues were common sources of uncertainty regardless of the degree of committee concern.","confidence":0.93,"paper":{"corpus_id":44162853,"title":"Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","url":"https://sah.borca.ai/papers/44162853"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_14ec172d01d3cf3cc629b30c9a353a0c","name":"comparators","description":"Alternative treatments or standards of care used to judge the relative effectiveness and value of cancer drugs.","types":["comparison element"],"url":"https://sah.borca.ai/concepts/co_14ec172d01d3cf3cc629b30c9a353a0c"},{"public_id":"co_30023ad931265e0758277cf5c0e7f470","name":"immaturity of survival data","description":"Incomplete or insufficiently mature survival outcome evidence in cancer drug trials or appraisals.","types":["evidence limitation"],"url":"https://sah.borca.ai/concepts/co_30023ad931265e0758277cf5c0e7f470"},{"public_id":"co_92fea6cf18541b4ff56392fa0aec311a","name":"degree of concern","description":"The level of uncertainty concern inferred from where committee comments appeared in structured NICE appraisal documents.","types":["proxy measure"],"url":"https://sah.borca.ai/concepts/co_92fea6cf18541b4ff56392fa0aec311a"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_50f79482a0c0ce49639d7297657ba38a"}